Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Current Assets Current Deferred Revenue Current Leases Current Taxes Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares

Cash Flow Statement

Daily Values

Growth Metrics

Others

Insight Molecular Diagnostics (IMDX) Inventory (2024 - 2026)

Insight Molecular Diagnostics' Inventory history spans 2 years, with the latest figure at $446000.0 for Q4 2025.

On a quarterly basis, Inventory rose 8.78% to $446000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $446000.0, a 8.78% increase, with the full-year FY2025 number at $446000.0, up 8.78% from a year prior.
Inventory hit $446000.0 in Q4 2025 for Insight Molecular Diagnostics, down from $471000.0 in the prior quarter.
Over the last five years, Inventory for IMDX hit a ceiling of $693000.0 in Q2 2025 and a floor of $232000.0 in Q3 2024.